Articles tagged with Platelet Counts
Scientists used CAR-T cell therapy to treat a patient with severe autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid antibody syndrome. The treatment achieved lasting remission without additional treatment for over a year.
Researchers at EHU developed a portable, cost-effective system for generating high-quality platelet-rich plasma (PRP), minimizing platelet activation and preserving therapeutic efficacy. The device uses gravity sedimentation and can extract up to 300 micro-liters of PRP from 1 milliliter of blood in just 40 minutes.
A phase III clinical trial showed efgartigimod significantly improved sustained platelet response and doubled platelet counts in patients with chronic ITP. The treatment demonstrated effectiveness across various patient demographics, with minimal side effects.
Biological systems have the potential to make mistakes, providing a starting point for generating new scientific questions. The authors propose a theoretical framework that describes the nature of mistake-making and its common processes, with applications to blood clotting.
Experts warn that cerebral venous sinus thrombosis (CVST) blood clots are rare but serious events associated with COVID-19 infections, not vaccines. Immediate screening and non-heparin anticoagulants can help diagnose and treat the condition. Most patients can recover fully with proper treatment.
A new study by University of Exeter researchers suggests that higher-end normal blood platelet counts may be indicative of an increased risk of cancer, particularly in older males. The research found a significant correlation between high platelet levels and the development of lung and colorectal cancers.
A study found that hypertensive adults with low platelet count and high homocysteine levels reduced their risk of first stroke by 73% with folic acid supplements. The treatment was particularly effective for patients at high risk, suggesting a potential cost-effective primary prevention strategy.
A blood test can predict which children are at risk of developing dengue shock syndrome, a life-threatening complication. Daily platelet counts and changes in platelet levels over time help identify patients who are most likely to develop the condition.
Pacritinib significantly reduces spleen size among people with very low levels of platelets, while a twice-daily dose improves symptoms. The study also showed that pacritinib is effective in treating patients who have previously been treated with ruxolitinib.
A new set of guidelines for platelet transfusion aims to reduce bleeding in adult patients, while a multidrug regimen shows higher remission rates for lupus nephritis patients in a randomized controlled trial.
Researchers have identified five novel gene mutations associated with elevated blood platelet counts in African Americans, a group at higher risk of stroke and worse outcomes after a heart attack. The study's findings could lead to the development of new drugs to prevent coronary artery disease and clot formation.
A study found that using electron beam sterilized dialyzers increased the risk of thrombocytopenia, a low platelet count associated with bleeding, in hemodialysis patients. The use of non-electron beam sterilized dialyzers reduced this risk.
Researchers at the University of Utah discovered that platelets can reproduce themselves in the circulation, increasing their numbers. This finding has significant implications for treating low platelet counts and transfusion medicine.
A new medication called Promacta has shown promising results in treating ITP, with 59% of patients achieving platelet counts at or over 50,000 per microliter of blood. The treatment works by stimulating the production of cells in bone marrow that form platelet cells in the blood.
The study presents a new combination therapy for previously untreated ITP, an investigational oral treatment for chronic ITP, and a low-dose platelet transfusion strategy. These approaches aim to minimize bleeding episodes in patients with platelet disorders.
A Phase 2 study found eltrombopag increased platelet counts in 74% of patients with low platelet counts and cirrhosis due to hepatitis C. The drug also allowed more patients to complete antiviral therapy, with 36-65% completing treatment at the lowest and highest doses.
A Phase 2 study found that eltrombopag elevated platelet counts to a safe level in over 75% of chronic ITP patients within two weeks, reducing bleeding symptoms. The therapy also showed similar incidence and severity of adverse effects compared to the placebo group.
Research found a significant association between decreased platelet count and the development of HIV-associated dementia. Platelet decline was linked to a two-fold increased risk of dementia within six to 12 months after baseline values.
Researchers found a close correlation between vancomycin exposure and severe thrombocytopenia with serious bleeding. The antibiotic was discontinued in most cases, resulting in normal platelet counts.
A long-term study showed that AMG 531 increased platelet counts in patients with immune thrombocytopenic purpura (ITP), with 47% of patients experiencing a durable response. The treatment was generally well-tolerated, but some serious adverse events were reported.
Research from the Women's Interagency HIV Study found that HIV-infected women with low platelet counts had a five-fold increased risk of dying due to any cause. The study also revealed that highly active antiretroviral therapy, such as HAART containing zidovudine, can boost platelet counts back to normal.
A study conducted at the Mayo Clinic found that gastrointestinal endoscopy assistants, trained under supervision, can perform large-volume paracenteses safely and efficiently, with a median procedure time of two hours. The practice has been shown to save physician time without increasing patient risk.
A French study found that intravenous immunoglobulin improved platelet counts in adults with AITP. The study also showed that oral steroids and placebo had similar efficacy rates. The researchers suggest judicious observation for patients without severe bleeding and recommend specific immune-based therapies.